The Diagnostics Industry Post-Covid: A Revival or Return to Baseline?
The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
The Diagnostics Industry Post-Covid: A Revival or Return to Baseline?
Published in MedTech Strategist
Authors: Wendy Diller, Oded Ben-Joseph, Craig Steger, and Thomas Joyce
Abstract:
The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
News
Outcome Capital Congratulates RealizedCare on the Acquisition by XRHealth
BOSTON– February 26, 2025 – Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, congratulates RealizedCare on the success of their company, and acquisition by XRHealth. Outcome Capital served as the exclusive strategic and financial advisor to RealizedCare. Through their digitally-powered care management triage platform and therapeutic solutions, RealizedCare […]
Read MoreResources
Outcome Capital Life Science Market Pulse, February 2025
Outcome Capital Life Science Market Pulse February 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
